-
| Exchange | NASDAQ |
|---|---|
| ISIN | US0167445008 |
| Sector | Healthcare |
| Industry | Biotechnology |
| CurrencyCode | USD |
| Beta | -0.07 |
|---|---|
| Market Cap | 19M |
| PE Ratio | None |
| Target Price | 5 |
| Dividend Yield | None |
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALLR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025